购物车 (0)

DIA会员及用户请点击登录

登录

忘记用户 ID？ or 忘记密码？

Not a Member?

创建账户并加入。

Tokyo Big Sight

2017 年 11 月 12 日 9:30 上午 - 2017 年 11 月 14 日 5:30 下午

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

14th DIA Japan Annual Meeting 2017

返回 Agenda

[V7-S3] Current Status on Counterfeit Medicines in Global and Issues on Japanese Market

Session Chair(s)

Yoshiaki Ohashi, PhD

Yoshiaki Ohashi, PhD

Audit and Supervisory Board Member

Chugai Pharmaceutical Co.,Ltd., Japan

The threat of counterfeit medicines is increasing worldwide, and it creates serious risks to patient safety. In particular, many cases of medicines purchased over the internet have been found to be counterfeit. Therefore, it is necessary that pharmaceutical companies take initiatives including implementation of anti-counterfeiting technologies and working with Customs and law enforcement agencies. In Japanese medicine market, it has been traditionally considered that counterfeit medicines would not be distributed, however, the “Harvoni” case indicates it would no longer true and can be a tip of the iceberg. In this session, trend of counterfeit medicines in global market, as well as the corrective actions, would be first introduced. And then, panelists from NPO, industry and academia will discuss potential risks and necessary actions in Japanese market, in order to secure patient safety as well as medicine quality.

Speaker(s)

Martin Blair

Global Situation Report 2016

Martin Blair

Pharmaceutical Security Institute (PSI), Thailand

Asia Pacific Regional Manager

Falsified Medicines in Japan

Kazuko Kimura, PhD

Kanazawa University, Japan

Prof. of Special-Appointment, MQS

ANTI-COUNTERFEIT ACTIVITIES AT HOFFMANN –LA ROCHE

Pius Waldmeier, PhD

F. Hoffmann-La Roche, Ltd., Switzerland

Head of Supply Chain Projects Mgt; Head of GRACC, Pharma Global Technical Ops

Scott Kammer, MA

A Company Framework, Objectives and Risk

Scott Kammer, MA

Takeda Pharmaceuticals U.S.A., Inc., United States

Director, Global Product Protection